# APVO catalysts: Aptevo Therapeutics Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/apvo/catalysts

> Aptevo Therapeutics Inc. (APVO) has 1 upcoming catalyst. The next is the ONUREG (azacitidine) trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for APVO?

Aptevo Therapeutics Inc. (APVO) has 1 upcoming catalyst. The next is the ONUREG (azacitidine) trial start, 1H 2027. Press release filed with the SEC (EX-99): "Aptevo expects the RAINIER dose optimization trial to conclude by year-end, with FDA interaction and initiation of a Phase 2 clinical trial anticipated in the first half of 2027" [Calendar and source filings](https://sec-api.dev/companies/apvo/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-431079, https://www.sec.gov/Archives/edgar/data/1671584/000119312526431079/apvo-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-10-26. Cite: https://sec-api.dev/companies/apvo/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Aptevo Therapeutics Inc. |
| Ticker | APVO (Nasdaq) |
| SEC CIK | 1671584 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/apvo |

## Cash runway

Cash $9.8M as of 2026-06-30; quarterly burn $5.5M; about 5.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-350559).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2024 | [Mipletamig trial start](https://sec-api.dev/pdufa/mipletamig) | APVO |  | completed | "The decrease was primarily due to lower preclinical spending and lower mipletamig trial costs as we concluded our Phase 1b dose expansion study and initiated the Phase 1b/2 dose optimization study in August of 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1671584/000095017025020467/apvo-20241231.htm)) |
| November 20, 2024 | [Mipletamig trial start](https://sec-api.dev/pdufa/mipletamig) | APVO |  | completed | "On November 20, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") announced that the first patient dosed in Aptevo's ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, supporting the continued overall efficacy trend seen in prior mipletamig AML studies." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-20241120.htm)) |
| November 20, 2024 | [ONUREG (azacitidine) trial start](https://sec-api.dev/pdufa/azacitidine) | APVO | Acute Myeloid Leukemia | completed | "Seattle, Washington, November 20, 2024 - Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today expanded on the potential of mipletamig, currently being evaluated as frontline therapy for the treatment of Acute Myeloid Leukemia (AML), in combination with standard of care venetoclax and azacitidine, noting the first patient dosed in the ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-ex99_1.htm)) |
| February 14, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "APTEVO THERAPEUTICS REPORTS 2024 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/apvo-ex99_1.htm)) |
| May 15, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "APTEVO THERAPEUTICS REPORTS 1Q25 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017025072594/apvo-ex99_1.htm)) |
| August 11, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Therapeutics Reports 2Q25 Financial Results And" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/apvo-ex99_1.htm)) |
| November 6, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Therapeutics Reports 3Q25 Financial Results And" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/apvo-ex99_1.htm)) |
| March 26, 2026 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Provides State of the Business Report and 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/apvo-ex99_1.htm)) |
| August 14, 2026 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/apvo-ex99_1.htm)) |
| 1H 2027 | [ONUREG (azacitidine) trial start](https://sec-api.dev/pdufa/azacitidine) | APVO |  | scheduled | "Aptevo expects the RAINIER dose optimization trial to conclude by year-end, with FDA interaction and initiation of a Phase 2 clinical trial anticipated in the first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312526431079/apvo-ex99_1.htm)) |

## Drugs

- [Mipletamig](https://sec-api.dev/pdufa/mipletamig): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/apvo/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "APVO catalysts: Aptevo Therapeutics Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/apvo/catalysts

```bibtex
@misc{secapidev_companies_apvo_catalysts_20261116,
  title        = {APVO catalysts: Aptevo Therapeutics Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/apvo/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_apvo_catalysts_20261116","title":"APVO catalysts: Aptevo Therapeutics Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/apvo/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
